Company overview
Hybrigenics Services offers fee-for-service R&D support with proprietary ULTImate Y2H platforms for protein-protein, drug-protein interaction studies, and target identification in drug discovery. They provide custom synthetic VHH nanobody selection, validation, and affinity maturation using their Hybribody library, animal-free process. Services extend to fundamental research, agrosciences, and partnerships with pharma, biotechs, and academia across therapeutic areas like oncology.
Hybrigenics Services is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include hybrigenics services, yeast two hybrid, y2h screening, vhh nanobodies, protein interactions, drug target identification.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.hybrigenics-services.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- hybrigenics services, yeast two hybrid, y2h screening, vhh nanobodies, protein interactions, drug target identification, nanobody selection
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are your core technological platforms?
- ULTImate Y2H for comprehensive protein interaction screening including drug-protein targets via patented cell-to-cell mating, and Hybribody for synthetic VHH nanobody selection, validation, and affinity maturation.
- Which industries and therapeutic areas do you serve?
- Pharma, biotechs, startups, agrosciences, and academia in oncology, cardiology, neurology, and plant biology for sustainable research.
- What is your experience with regulatory or drug discovery needs?
- Specialized Y2H adapted for drug discovery to identify direct compound targets; collaborations like with Servier for DUB target validation in oncology and other fields.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
